The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial per Judge, PK, Tuttle, KR, Staplin, N, Hauske, SJ, Zhu, D, Sardell, R, Cronin, L, Green, JB, Agrawal, N, Arimoto, R, Mayne, KJ, Sammons, E, Brueckmann, M, Shah, SV, Rossing, P, Nangaku, M, Landray, MJ, Wanner, C, Baigent, C, Haynes, R, Herrington, WG

Altres autors: “…EASi-KIDNEY Steering Committee…”